Treatment of postmenopausal women with osteoporosis with PTH(1–84) for 36 months: treatment extension study

José Zanchetta(Universidad del Salvador), Willem F. Lems(Amsterdam University Medical Centers), Spyros Aslanidis(Hippocration General Hospital), César E. Bogado(Universidad del Salvador), John Fox(Arrien Pharmaceuticals (United States)), H. Greisen, Carlo Cisari(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Current Medical Research and Opinion
October 5, 2010
10.1185/03007995.2010.524121
Cited by 18

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
|Arthritis & Rheumatism|2009|497